Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Hypogonadism

Hypogonadism

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hypogonadism

55 trials tracked for Hypogonadism: 27 in phase 3 or 4 and 8 with published results. The most-cited published study has 279 citations.

55Trials tracked
27Phase 3 & 4
0Recruiting
8With published results
Phase distribution
Phase 4 13 Phase 3 14 Phase 2 21 Phase 1 6 Other / NA 1
  1. Phase 4 Testosterone Replacement in Men With Diabetes and Obesity Completed · 279 cited
  2. Phase 4 Testosterone Replacement in Older Men and Atherosclerosis Progression Completed · 172 cited
  3. Phase 4 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men Completed · 126 cited
  4. Phase 3 A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937) Completed · 43 cited
  5. Phase 4 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Completed · 38 cited
  6. Phase 3 Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism Completed · 32 cited
Show 44 more trials
  1. Phase 4 Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism Completed · 15 cited
  2. Phase 4 A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism Completed · 1 cited
  3. Phase 4 Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™ Completed
  4. Phase 4 Testosterone for Peripheral Vascular Disease Completed
  5. Phase 4 A Study to Evaluate Androderm®'s Effect on Blood Pressure in Adult Hypogonodal Male Participants Completed
  6. Phase 4 A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism Completed
  7. Phase 4 Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism Completed
  8. Phase 4 TRADE-Testosterone Replacement and Dutasteride Effectiveness Completed
  9. Phase 4 The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel Completed
  10. Phase 3 Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men Completed
  11. Phase 3 Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism Completed
  12. Phase 3 Exercise and Testosterone Therapy in Elderly Men With Physical Frailty Completed
  13. Phase 3 A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men Completed
  14. Phase 3 Testopel ® vs. Generic Testosterone Pellets. Completed
  15. Phase 3 Testosterone Replacement Therapy in Chronic Spinal Cord Injury Completed
  16. Phase 3 A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations Completed
  17. Phase 3 A Study of Fortigel Testosterone Gel 2% in Males With Low Testosterone Completed
  18. Phase 3 A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy Completed
  19. Phase 3 A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations Completed
  20. Phase 3 A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism Completed
  21. Phase 3 Testosterone Treatment for Hypogonadal Men Completed
  22. Phase 2 Efficacy of an Intranasal Testosterone Product Completed
  23. Phase 2 Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial. Completed
  24. Phase 2 Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism Completed
  25. Phase 2 Efficacy and Tolerability of an Intra-Nasal Testosterone Product Completed
  26. Phase 2 Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception Completed
  27. Phase 2 Pharmacokinetic Study of Testosterone Enanthate Completed
  28. Phase 2 Effects of Testosterone Gel on Carbohydrate and Lipid Metabolism In Elderly Obese Men Completed
  29. Phase 2 Oral Testosterone for the Treatment of Hypogonadism in Males Completed
  30. Phase 2 A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels Completed
  31. Phase 2 Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems Completed
  32. Phase 2 Oral Testosterone for the Treatment of Hypogonadism Completed
  33. Phase 2 Phlebotomy Study of Testosterone Undecanoate Completed
  34. Phase 2 Administration of Kisspeptin in Patients With Hyperprolactinemia Completed
  35. Phase 2 Anastrozole Administration in Elderly Hypogonadal Men Completed
  36. Phase 2 A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations Completed
  37. Phase 2 Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men Completed
  38. Phase 2 Testosterone and Growth Hormone for Bone Loss in Men Completed
  39. Phase 2 The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate Completed
  40. Phase 2 Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men Completed
  41. Phase 2 Clomiphene Citrate for the Treatment of Low Testosterone Associated With Chronic Opioid Pain Medication Administration Completed
  42. Phase 2 Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo Completed
  43. Phase 1 A Bioequivalence Study of Testosterone Cypionate in Hypogonadal Males Completed
  44. Phase 1 CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy Completed

Showing the 50 most-cited and recently-updated of 55 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Hypogonadism: what the trials found

Various testosterone delivery methods, including gels [2, 6], nasal gels 10, transdermal systems [8, 22], and injectable products [7, 15, 19], have been evaluated for the treatment of hypogonadism. Topical testosterone solutions demonstrated a significant increase in serum testosterone levels (p<0.001) with 94.7% of participants achieving normal levels 11. Oral testosterone undecanoate was also shown to reach eugonadal ranges in a majority of subjects 17.

Clinical improvements associated with testosterone therapy include significant increases in sexual arousal, interest, and drive (SAID scores) and improved energy diary (HED) scores 21. Additionally, transdermal systems were associated with increases in lean tissue mass 22, while transdermal gels showed a statistically significant increase in total lean body mass 18.

Safety data regarding testosterone use include observations on cardiovascular markers; for example, coronary artery calcium scores were recorded following AndroGel use 2. In large-scale studies of AndroGel, the incidence of high-grade prostate cancer was low (3-5 cases) 3. One study noted that patients receiving Aveed did not require dose increases in antihypertensive medications 7.

For the clinician treating this condition

  • Multiple testosterone delivery methods (gel, nasal, transdermal, and injectable) are established for managing hypogonadism, with topical solutions showing high success rates in achieving normal serum levels [10, 11].
  • clinical improvements include significant gains in sexual function and energy scores 21, as well as increases in lean body mass or tissue [18, 22].
  • Safety monitoring for cardiovascular markers and prostate health is supported by data from large-scale trials of various testosterone formulations [2, 3].

AI synthesis of 9 cited trials, updated Jun 27, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meta-analysis shows testosterone replacement therapy increases clinical fracture risk in hypogonadal men compared to placebo
Orthopedics & Sports Medicine Meta-analysis
Meta-analysis shows testosterone replacement therapy increases clinical fracture risk in hypogonadal men compared to placebo Testosterone therapy raises fracture risk in hypogonadal men
A systematic review of 2,711 hypogonadal men found that testosterone replacement therapy significantly increased the risk of clinical fractu…
A large review found that men with low testosterone taking replacement therapy had a higher risk of clinical fractures compared to those on …
Jun 5, 2026
Testosterone gel fails to normalize serum levels in critically ill ICU patients in pilot RCT
Emergency Medicine RCT
Testosterone gel fails to normalize serum levels in critically ill ICU patients in pilot RCT Can testosterone gel help critically ill men? A small study finds no clear benefit
A pilot RCT of 30 critically ill ICU patients on vasopressors and mechanical ventilation found 14-day testosterone gel administration did no…
Testosterone gel did not improve hormone levels or safety in critically ill men needing breathing machines and blood pressure support.
Apr 2, 2026